News about "Merck"

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck discontinues the clinical development of nemtabrutinib and all three Phase 3 BELLWAVE trials following a benefit-risk assessment that raised concerns about the investigational BTK inhibitor.

Merck | 20/11/2026 | By News Bureau

Merck Initiates Phase 3 ENHANCE-3 Trial of Ohtuvayre for COPD Exacerbation Prevention

Merck Initiates Phase 3 ENHANCE-3 Trial of Ohtuvayre for COPD Exacerbation Prevention

Merck initiates the phase 3 ENHANCE-3 clinical trial to evaluate Ohtuvayre for preventing COPD exacerbations in adults receiving standard-of-care treatment.

Merck | 05/11/2026 | By News Bureau

Merck to Acquire Silence Therapeutics for Rare Disease siRNA

Merck to Acquire Silence Therapeutics for Rare Disease siRNA

Merck has entered into a definitive agreement to acquire biotech company Silence Therapeutics, focused on siRNA-therapies in areas of high unmet need.

Merck | 21/10/2026 | By News Bureau |  117

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Merck | 01/10/2026 | By News Bureau |  155

FDA Updates Winrevair Label With Phase 3 HYPERION Data

FDA Updates Winrevair Label With Phase 3 HYPERION Data

Merck’s Winrevair label has been updated by the US FDA to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension.

Merck | 23/09/2026 | By News Bureau |  206

Japan Approves Merck's Keytruda Qlex for Subcutaneous Use

Japan Approves Merck's Keytruda Qlex for Subcutaneous Use

Merck’s Keytruda Qlex receives MHLW approval in Japan for subcutaneous use across all locally approved Keytruda indications.

Merck | 22/09/2026 | By News Bureau |  131

Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC

Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC

Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.

Merck | 19/09/2026 | By News Bureau |  136

Merck Expands Jigani Facility to Boost Life Science Manufacturing

Merck Expands Jigani Facility to Boost Life Science Manufacturing

Merck has invested approximately Euro 13 million to expand its Jigani, Bengaluru facility with new biological buffer manufacturing capabilities.

Merck | 18/09/2026 | By News Bureau |  265

Merck Delivers Robust Q2 2026 Performance

Merck Delivers Robust Q2 2026 Performance

Merck reported strong Q2 2026 results with 4.1 percent organic sales growth, higher EBITDA, upgraded full-year guidance and planned Bio-Techne acquisition.

Merck | 06/08/2026 | By News Bureau |  183

Merck Wins US FDA Breakthrough Therapy Designation Status for Enpatoran in Lupus

Merck Wins US FDA Breakthrough Therapy Designation Status for Enpatoran in Lupus

Merck has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for enpatoran in lupus patients with active skin manifestations, advancing a potential first approved treatment for cutaneous lupus.

Merck | 09/07/2026 | By News Bureau |  130


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members